



**Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)**  
**Federal Office of Consumer Protection and Food Safety**  
**Mauerstraße 39-42**  
**10117 Berlin**  
**(Germany)**

## **MUTUAL RECOGNITION PROCEDURE**

### **PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT**

Revertor 5 mg/ml solution for injection for dogs

**Date: February 2008**

Ostlandring 13

31303 Burgdorf

Germany

Application for Mutual Recognition Procedure  
Publicly available assessment report

## MODULE 1

### PRODUCT SUMMARY

EU Procedure number	DE/V/0123/001/MR
Name, strength and pharmaceutical form	Revertor 5 mg/ml solution for injection for dogs
Applicant	CP-Pharma Handelsges. mbH Ostlandring 13 31303 Burgdorf Germany
Active substance	Atipamezole hydrochloride
ATC Vetcode	QV03AB90
Target species	Dogs
Indication for use	Atipamezole hydrochloride is a selective alpha 2-agonist and indicated for reversal of the sedative effects of medetomidine.

Ostlandring 13  
31303 Burgdorf  
Germany

Application for Mutual Recognition Procedure  
Publicly available assessment report

---

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicinal Agencies website ([www.hma.eu](http://www.hma.eu)).

Ostlandring 13  
31303 Burgdorf  
Germany

Application for Mutual Recognition Procedure  
Publicly available assessment report

## MODULE 3

### PUBLIC ASSESSMENT REPORT

Legal basis of original application	Application in accordance with Article 13 of Directive 2001/82/EC as amended.
Date of completion of the original Mutual recognition procedure Decentralised procedure	24.10.2007
Date product first authorised in the Reference Member State (MRP only)	27.02.2007
Concerned Member States for original procedure	Austria; Belgium; Czech Republic; Denmark; Spain; Finland; France; Hungary; Ireland; Italy; Lithuania; Latvia; The Netherlands; Norway; Poland; Portugal; Sweden; Slovakia; United Kingdom

#### I. SCIENTIFIC OVERVIEW

Revertor from CP-Pharma, is a generic product to Antisedan marketed in Germany since 1991 (Reference number 23554.00.00). Revertor is a solution for injection and approved for reversal of the sedative effects of medetomidine in dogs.

Essential similarity of Revertor and the reference product Antisedan was demonstrated according to the relevant EU guidelines. The initial application for Antisedan was assessed before there was a requirement to have a public assessment report, therefore, no details in this section are available.

#### II. QUALITY ASPECTS

##### A. *Composition*

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

Ostlandring 13  
31303 Burgdorf  
Germany

Application for Mutual Recognition Procedure  
Publicly available assessment report

---

The product contains atipamezole hydrochloride 5 mg / ml and methyl parahydroxybenzoate, sodium chloride and water for injections.

The product is filled into 10 ml uncoloured glass vials. The vials are closed with rubber bungs. The bungs are secured with aluminium crimp caps. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the presence of a preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

### ***B. Method of Preparation of the Product***

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

The product is manufactured using conventional manufacturing techniques. Process validation for full-scale batches will be performed post-authorisation.

### ***C. Control of Starting Materials***

The active substance is atipamezole hydrochloride, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

An Active Substance Master File (ASMF) has been submitted to the authorities.

### ***D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies***

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

### ***E. Control on intermediate products***

***Not applicable.***

### ***F. Control Tests on the Finished Product***

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

Ostlandring 13  
31303 Burgdorf  
Germany

Application for Mutual Recognition Procedure  
Publicly available assessment report

---

justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

### **G. Stability**

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

The claim of a 28 day stability after broaching is based on the demonstration of stability for a batch broached and stored 28 days at 20 - 25°C.

### **H. Genetically Modified Organisms**

**Not applicable.**

### **J. Other Information**

**None.**

## **III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)**

As this is a generic application according to Article 13 of Directive 2001/82/EC based on the essential similarity of Revertor and the reference product Antisedan, results of pharmacological and toxicological tests are not required.

The applicant has made full reference to the SPC of the reference product Antisedan granted in Germany. However, as this was not completely identical to the SPCs authorised for this product in other concerned member states, efforts have been made during the mutual recognition procedure to produce a harmonised overall accepted product literature for Revertor. Warnings and precautions as listed in the product literature are adequate to ensure safety of Revertor to the user and the environment.

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

Ostlandring 13  
31303 Burgdorf  
Germany

Application for Mutual Recognition Procedure  
Publicly available assessment report

---

#### **IV. CLINICAL ASSESSMENT (EFFICACY)**

As this is a generic application according to Article 13 of Directive 2001/82/EC based on essential similarity of Revertor and the reference product Antisedan, results of preclinical and clinical studies are not required. The efficacy claims for Revertor are equivalent to those of the reference product Antisedan.

Ostlandring 13  
31303 Burgdorf  
Germany

Application for Mutual Recognition Procedure  
Publicly available assessment report

---

## **V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

When used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

Ostlandring 13

31303 Burgdorf

Germany

Application for Mutual Recognition Procedure  
Publicly available assessment report

---

## **MODULE 4**

### **POST-AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicinal Agencies website ([www.hma.eu](http://www.hma.eu)).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

<None>